Core Viewpoint - Xencor (XNCR) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often adjust their valuations based on changes in earnings estimates, leading to significant stock price movements [4]. Company Performance and Outlook - Xencor is projected to earn -$3.71 per share for the fiscal year ending December 2024, reflecting a year-over-year decline of 78.4% [8]. - Despite the negative earnings projection, analysts have raised their estimates for Xencor, with the Zacks Consensus Estimate increasing by 11.1% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a 'Strong Buy' or 'Buy' rating [9][10]. - Xencor's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [11].

Xencor (XNCR) closed the last trading session at $26.60, gaining 23.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $35 indicates a 31.6% upside potential.The average comprises 11 short-term price targets ranging from a low of $22 to a high of $60, with a standard deviation of $9.77. While the lowest estimate indicates a decline of 17.3% from the current price level, the most op ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Core Viewpoint - Xencor (XNCR) shares have increased by 5.9% recently, with a mean price target of $35.42 suggesting a potential upside of 53.5% from the current price of $23.07 [1] Price Targets - The average price target consists of 12 estimates ranging from a low of $20 to a high of $60, with a standard deviation of $11.19, indicating variability among analysts [2] - The lowest estimate suggests a decline of 13.3%, while the highest indicates a potential upside of 160.1% [2] - A low standard deviation signifies a strong agreement among analysts regarding the stock's price movement [7] Analyst Sentiment - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [9] - Over the past 30 days, six earnings estimates for XNCR have been revised upward, leading to a 7.9% increase in the Zacks Consensus Estimate [10] - XNCR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [11] Caution on Price Targets - Solely relying on price targets for investment decisions may not be prudent, as they can often mislead investors [5][8] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [6]

From a technical perspective, Xencor, Inc. (XNCR) is looking like an interesting pick, as it just reached a key level of support. XNCR's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer-term movin ...

Xencor (XNCR) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 27.55%. A quarter ago, it was expected that this biotech developing antibodies for severe autoimmune/allergic diseases and cancer would post a loss of $0.85 per share when it actually produced a loss of $1.07, delivering a surprise ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________________________ FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |----------------------------------------------------------------------|--------------------------- ...

Exhibit 99.1 Xencor Reports Third Quarter 2024 Financial Results PASADENA, Calif-- Nov. 6, 2024-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the third quarter ended September 30, 2024 and provided a review of recent business and clinical-stage program updates. "In September, we provided updates across our clinical pipeline of XmAb® bispecific T-cell engage ...

Shares of Xencor (XNCR) have gained 7.9% over the past four weeks to close the last trading session at $21.01, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $35.33 indicates a potential upside of 68.2%.The average comprises 12 short-term price targets ranging from a low of $20 to a high of $60, with a standard deviation of $11.22. While the lowest estimate indicates a decline ...

Core Viewpoint - Xencor (XNCR) shares have shown a modest gain of 0.4% over the past month, closing at $21.13, with analysts suggesting a potential upside of 67.2% based on a mean price target of $35.33 [1] Price Targets and Analyst Consensus - The average price target for XNCR is derived from 12 short-term estimates, ranging from a low of $20 to a high of $60, with a standard deviation of $11.22, indicating variability in analyst predictions [2] - The lowest estimate suggests a decline of 5.4%, while the highest indicates an upside of 184%, highlighting the range of opinions among analysts [2] - A low standard deviation signifies strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [7] Earnings Estimates and Potential Upside - Analysts have shown increasing optimism about XNCR's earnings prospects, as evidenced by a trend of higher EPS estimates, which correlates with potential stock price increases [9] - Over the past 30 days, three earnings estimates have been revised upward, leading to a 1.4% increase in the Zacks Consensus Estimate for the current year [10] - XNCR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside [11]